The unfolded protein response (UPR) is a stress response of the endoplasmic reticulum (ER), the first compartment of the secretory pathway. The UPR is activated in non-tangle bearing neurons in Alzheimer's disease (AD) brain, indicating it is an early phenomenon. We found that the level of Rab6, implicated in anterograde and retrograde trafficking in the secretory pathway, is increased in brains of AD patients. Rab6 expression, closely correlated with the extent of UPR activation, is not controlled by the UPR. This suggests that Rab6 and UPR activation are both increased in response to early pathogenic changes in AD. Here we demonstrate that Rab6 modulates the UPR, increased levels inhibit whereas decreased levels augment UPR induction. Rab6 is not involved in the initial phase of the UPR, it only affects the UPR after prolonged ER stress. We propose that Rab6 is involved in the recovery from an ER stress insult. The increased Rab6 levels in AD brain in combination with UPR activation suggest that a failure to recover from ER stress may contribute to neurodegeneration in AD. The Rab6 mediated recovery pathway may provide a target to selectively inhibit the destructive pathways of the UPR.
Introduction
It is pivotal for therapeutic intervention to target early pathogenic pathways in Alzheimer's disease (AD). We reported activation of the unfolded protein response (UPR) as an early event in neurons in AD brain 62, 64 . The UPR is a stress response of the endoplasmic reticulum (ER). Several homeostatic and biosynthetic pathways are located in the ER: it is a site for Ca 2+ homeostasis, redox balance, lipid synthesis and importantly the synthesis and folding of membrane bound and secretory proteins. Disturbance of ER homeostasis leading to intraluminal protein misfolding (termed ER stress) results in activation of the UPR 66, 68 .
The UPR signals via three sensor molecules in the ER membrane, double-stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK), inositol requiring kinase 1 (Ire1) and activating transcription factor 6 (ATF6). These sensor molecules are bound by the ER chaperone binding immunoglobulin (heavy chain) protein/glucose-regulated protein 78 (BiP/GRP78) under normal conditions. In case of ER stress, BiP releases from the sensors and the three signalling pathways of the UPR are activated. The PERK pathway is involved in translational regulation. Activated PERK phosphorylates the translation initiation factor eIF2α resulting in an overall attenuation of translation and selective translation of specific mRNAs by upregulation of activating transcription factor 4 (ATF4). Activation of Ire1 leads to splicing of the XBP1 mRNA, resulting in production of the active transcription factor XBP1 (spliced). Another transcription factor is produced by activation of ATF6: BiP release allows AT-F6(-p90) to traffic to the Golgi, where it is sequentially processed by the site-1 and site-2 proteases to render the active ATF6-p50 transcription factor.
Activation of the UPR is initiated to restore homeostasis in the ER. The inhibition of protein synthesis is aimed to temporarily reduce the protein load in the ER. In addition, the expression of proteins that assist in protein folding (e.g. BiP) is increased 229, 230 . Also, the proteolysis of aberrant proteins is facilitated by upregulation of components of the ER associated degradation (ERAD) machinery and activation of autophagy 161, [231] [232] [233] [234] . Furthermore, the expression of pro-apoptotic proteins like cAMP response element-binding (C/EBP) homologous protein (CHOP) is increased. If the homeostasis is restored, the UPR will be switched off, but prolonged activation will result in cell death 235, 236 . During UPR activation the regular function of the ER as major protein factory and first compartment in the secretory pathway is compromised. This will affect several vesicle transport routes, which is particularly problematic for cells that are very dependent on transport of vesicles for proper function, like neurons. Rab proteins, members of the small GTPase super family, are important regulators of vesicle transport via interactions with effector proteins and motor proteins 180 . Rab6, in its active form a Golgi resident protein, has been implicated in retrograde and anterograde trafficking in the secretory pathway 206, 208, [237] [238] [239] . We have previously found that the levels of Rab6 are increased in AD temporal cortex, in close correlation with the extent of UPR activation 226 . We showed that Rab6 expression is not controlled by the UPR, suggesting that increased Rab6 and UPR are independent events and this is in response to early pathogenic changes in AD. In this study we investigated the functional connection between Rab6 and the UPR in more depth. Our data suggest a novel pathway that may be employed to selectively modulate the destructive effects of prolonged ER stress, which is of potential interest for AD that is characterized by UPR activation early in the pathogenesis.
Materials and methods

Materials
Cell culture media and reagents were obtained from Gibco/Invitrogen (Carlsbad, CA, USA), plasmid selection reagents were from Invitrogen (Carlsbad, CA, USA) and other chemicals were from Sigma (St. Louis, MO, USA), unless indicated otherwise.
Plasmids and generation of TREx-HeLa-Rab6 Q72R cell line Expression plasmids pSVSport1 Rab6A Wt, -Q72R (constitutive active) and -T27N (dominant negative)
199 were a kind gift from C. C. Hoogenraad. All three Rab6A cDNA's were constructed to include a 5' Myc-tag. The Myc-Rab6A Q72R cDNA was cloned into the pcDNA4/TO vector (Invitrogen) using EcoRI and XbaI restriction sites. TREx-HeLa cells (Invitrogen) were stably transfected with pcDNA4/TO Myc-Rab6A Q72R, according to manufacturer's protocol, to generate TREx-HeLa-Rab6 Q72R cell lines. Selection of double positive clones was performed with Blastidicin (20 µg/mL) and Zeocin (1 mg/mL). Single clones were selected and inducible expression of transgenic Myc-Rab6A Q72R was verified on western blot.
Cell culture and treatment
HeLa-and TREx-HeLa-Rab6 Q72R cells were cultured in Dulbecco's modified Eagle medium (DMEM) with GlutaMAX supplemented with 10% (v/v) fetal calf serum (FCS, Sigma), 100 U/mL penicillin and 100 µg/mL streptomycin. Cell culture medium for TREx-HeLa-Rab6 Q72R cells was additionally supplemented with 5 µg/mL Blasticidin and 400 µg/mL Zeocin to maintain plasmid selection. TREx-HeLa-Rab6 Q72R cells were plated in a 12 wells plate at a density of 2.10 5 cells per well (on poly-L-lysine coated glass coverslips for immunofluorescence) and transgenic Myc-Rab6 Q72R expression was initiated by culturing in the presence of 1 µg/mL tetracycline (Tet) for at least 24 hours before treatment. CHO-ATF6 cells were previously described
240
, and were maintained in DMEM/Ham's F12 (1:1) with GlutaMAX supplemented with 7.5% (v/v) FCS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 250 µg/mL hygromycin-B to maintain stable 3xFLAG-ATF6 expression. All cells were incubated at 37°C, 5% CO 2 and 95% humidity. Cells were treated with tunicamycin at the indicated times and concentrations. To allow the cells to recover from tunicamycin induced ER stress, cells were washed once with complete medium without tunicamycin and subsequently incubated on complete medium without tunicamycin.
Plasmid and siRNA transfection
Transfections were performed with Lipofectamin 2000 Transfection Reagent (Invitrogen) according to manufacturer's protocol. For plasmid transfection, cells were seeded at a density of 8.10 4 or 2.10 5 cells per well (12 wells plate) for HeLa or CHO-ATF6 cells, respectively. Cells were transfected with 1.6 µg/mL plasmid DNA and treatment was started 24-36 hours after transfection.
The siRNA duplexes were prepared by Sigma/Proligo. The sequence of the scramble siRNA duplex was (sense: 5' r(AGUACUGCUUACGAUACGG)d(TT) 3') and the sequences of Rab6 siRNA duplex 1 (sense: 5' r(GACAUCUUUGAUCACCAGA)d(TT) 3') and duplex 2 (sense: 5' r(CACCUAUCAGGCAACAAUU)d(TT) 3') were previously published elsewhere
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. For Rab6 knockdown in HeLa cells duplex 1 was used and for Rab6 knockdown in CHO-ATF6 cells duplex 2 was used. For mRNA knockdown with siRNA, cells were seeded at a density of 2.10 4 cells per well (12 wells plate). Cells were transfected with 25 nM siRNA and treatment was started 72 hours after knockdown initiation.
SDS-PAGE and western blotting
Cells were harvested by scraping with a rubber policeman in 1% (v/v) Triton X-100 PBS lysis buffer supplemented with protease inhibitors (either Leupeptin and PMSF, or Complete protease inhibitors from Roche, Penzberg, Germany). TBS replaced PBS and PhosSTOP (Roche) was added in the lysis buffer for peIf2α western blots. Cell lysates were vigorously mixed, incubated on ice for 5 minutes, and centrifuged for 5 minutes at 20.000xg at 4°C. Supernatant protein content was determined by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). Equal amounts of protein were loaded in each lane on a gel. Cell lysates were separated on appropriate percentage polyacrylamide gels, 8% for BiP, 10% for ATF6 and peIF2α, and 12% for Rab6. Western blotting analysis was performed as described previously 169 . The antibodies used in this study are listed in table 1.
Immunofluorescence
For immunofluorescence stainings, cells were plated on glass coverslips. After treatment, cells were washed three times in ice-cold PBS, fixed in 4% (w/v) paraformaldehyde, 4% (w/v) sucrose (Merck, Darmstadt, Germany) in PBS for 5 minutes at room temperature, washed three times with ice-cold PBS, permeabilized with (pre-cooled) methanol for 5 minutes at -20°C, and washed three times with ice-cold PBS before immunostaining. The following steps were performed at room temperature. Coverslips with cells were blocked in 0.1% (w/v) BSA fraction V, 0.05% (w/v) saponin in PBS for 30 minutes. CHOP antibody (table 1) incubation was performed in 1% (w/v) BSA and 0.05% (w/v) saponin in PBS for 1 hour. Cells on glass slides were washed three times in block buffer before half an hour incubation with the Cy3 labeled secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA) in the same buffer as the primary antibody. For detection of overexpressed Rab6, cells were washed and incubated (as described for primary antibodies) with directly labeled FITC anti-Myc after CHOP secondary antibody incubation. Cells on coverslips were washed three times in block buffer, before counterstain with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, 1.3 µM) was applied to the cells for 5 minutes. Coverslips were rinsed in PBS, air dried, and mounted on glass slides with Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA, USA) and sealed with nail polish. Images were captured using a VANOX AHBT3 microscope (Olympus, Shinjuku, Tokyo, Japan) equipped with a digital camera. The CHOP positive nuclei were quantified from seven fields of view per condition. 
Western blotting
For western blotting, incubations with peIF2α were performed according to manufacturer's protocol, all other antibody incubations were performed 1:1000 in 2.5% (w/v) milk in PBS-T (0.05%, v/v). Incubations for immunofluorescence with CHOP antibody from Cell Signaling was performed according to manufacturer's protocol, all other incubations were performed 1:200 in 1% (w/v) BSA, 0.05% (w/v) saponin in PBS. The CHOP antibody from Cell Signaling was used for figures 1 and 2, and the antibody from Santa Cruz was used for supplementary figure 1.
RNA isolation and cDNA synthesis
Cells were lysed and scraped in TRIzol Reagent (Invitrogen) and organic-and aqueous phase separation was performed by mixing with chloroform (Merck). Subsequent RNA isolation was performed either manually (according to the manufacturer's protocol) or automated with an RNeasy MiniKit on a Qiacube (Qiagen, Venlo, the Netherlands; according to manufacturer's protocol). RNA purity and integrity were assessed on a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA) and on a 0.8% (w/v) agarose gel (2.5 µg/mL ethidium bromide).
cDNA synthesis was performed on 0.5-1.0 µg of RNA per reaction (RNA sample quantities do not vary within experiments) using a SuperScript II Reverse Transcrip-tase Kit (Invitrogen). Priming of mRNA poly-A tails was performed with 125 pmol oligo(dT)12-VN primer in a final volume of 10 µL and was incubated at 70°C for 10 minutes. MgCl 2 (2 mM), dNTPs (0.5 mM each), 5 µL 5x First-Strand Buffer and 100 U SuperScript II reverse transcriptase were added to the primed mRNAs in a final volume of 25 µL per reaction and incubated at 42°C for one hour. The reverse transcription reaction was stopped by incubation at 70°C for 10 minutes.
Real-Time qPCR
Per sample, 1 µL cDNA was pipetted in triplicate into a 384 wells plate and dried in a DNA110 SpeedVac (Thermo Savant). qPCR mixtures were prepared as described previously
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. Probe and primer combinations are listed in table 2. qPCR was performed on a LightCycler 480 system (Roche) with the following PCR program: 10 minutes denaturation at 95°C, followed by 45 cycles of denaturation at 95°C for 10 seconds, annealing at 58°C for 20 seconds and elongation at 72°C for 1 second (including signal acquisition), the PCR program was finalized by a 10 seconds cool down at 40°C. Results were analyzed using the LightCycler 480 software (version 1.5.0.39) and PCR efficiencies were calculated using LinRegPCR application (version 12.10,241) . All data are presented as mean±SD from a single experiment. The magnitude of the normalized values between experiments may vary. For statistical analyses the unpaired two-tailed Student's T-test was performed. Differences were accepted as statistically significant at p≤0.05. 
Results
Rab6 overexpression attenuates the UPR
To investigate the effect of Rab6 function on the UPR, Rab6 was overexpressed in a HeLa cell model. fig. 1D ), the strongest effect is observed at 0.5 µg/mL tunicamycin (mock 11.1±0.9 versus Rab6 4.2±0.3).
To verify these findings on mRNA level, BiP and CHOP protein inductions were analyzed in the presence or absence of Rab6 overexpression. Tunicamycin treatment results in the induction of BiP as determined by western blotting (fig. 1E ). Rab6 overexpression clearly reduces the BiP protein induction in response to tunicamycin elicited ER stress ( fig. 1E) . To determine the effect of Rab6 on CHOP protein expression, Rab6 overexpressing cells were identified by immunofluorescent staining, detecting the myctag of the exogenous Rab6 ( fig. 1F ). Treatment with tunicamycin increases the number of CHOP positive nuclei, these are predominantly observed in cells which have low or no Rab6 transgene expression; CHOP expression is reduced in Rab6 overexpressing cells.
These results are supported by a similar experiment in TREx-HeLa Q72R, a stable cell line with inducible expression of Rab6 Q72R (a constitutive active mutant of Rab6). Rab6 Q72R overexpression induced by tetracylin (suppl. fig. 1A ) is comparable to the overexpression in the transiently Rab6 (Wt) transfected HeLa cells ( fig. 1B ) and these cells are similarly responsive to tunicamycin treatment. Interestingly, constitutive active Rab6 also reduces BiP induction (suppl. fig. 1B ). The number of CHOP positive nuclei after tunicamycin treatment were reduced from 28% to 19%, by Rab6 Q72R overexpression, indicating that the nuclear translocation of CHOP is reduced (suppl. fig. 1C ). These results further support the finding that Rab6 reduces UPR activation.
To investigate whether the effect of Rab6 overexpression on the UPR is protective or cytotoxic, HeLa cells were transfected with Rab6 and with the tunicamycin induced toxicity was analyzed by phase contrast microscopy. This shows a concentration dependent cell loss as result of the tunicamycin treatment in the mock transfected cells (suppl. fig. 2 ). In contrast, the Rab6 overexpressing cells are more resistant to tunicamycin induced cell toxicity. This result indicates that increased Rab6 levels are protective during ER stress, which correlates with the reduced expression of the pro-apoptotic protein CHOP in cells which overexpress Rab6.
Rab6 knockdown increases the UPR
Knockdown of Rab6 by siRNA transfection was performed in HeLa cells to test whether this could affect the UPR. Rab6 knockdown was analyzed by qPCR ( fig. 2A ) and by western blot (fig. 2B) . Induction of the UPR was established by 20 hours treatment with different concentrations of tunicamycin. The response of the UPR was assessed on mRNA level by qPCR. Tunicamycin treatment increases the expression of the UPR markers BiP ( fig. 2C ) and CHOP ( fig. 2D ). Cells with reduced Rab6 levels, however, showed higher inductions of both BiP ( fig. 2C ) and CHOP mRNA ( fig. 2D ). BiP mRNA levels are increased 3-fold in Rab6 compared to scramble siRNA transfected cells at 0.2 µg/mL tunicamycin (2.1±0.4 versus 7.0±1.6, mean±SD) and are 1.5-fold increased at 0.5 µg/mL tunicamycin (5.6±0.9 versus 8.8±1.3, fig. 2C ). For CHOP mRNA a 2-fold augmentation is observed at 0.2 µg/mL tunicamycin (8.3±1.3 versus 18.3±4.5). The CHOP response levels out at 0.5 µg/mL tunicamycin ( fig. 2D ).
Merge Rab6 Modulates the unfolded PRotein ResPonse
The effect of Rab6 knockdown on the UPR was verified on protein level. BiP protein shows a dose dependent response to the tunicamycin treatment. As expected, Rab6 knockdown results in an additional increase of the BiP response ( fig. 2E ). CHOP nuclear localization was determined by immunofluorescense. Rab6 knockdown results in a stronger tunicamycin induced nuclear and overall CHOP staining as compared to scramble siRNA treated cells (fig. 2F ). These results show that Rab6 knockdown has an opposite effect on UPR activation compared to Rab6 overexpression, the UPR is increased upon Rab6 knockdown. Taken together, these data demonstrate that Rab6 function has a negative modulatory effect on the UPR.
Rab6 has no effect on the initial phase of the UPR Rab6 may exert its modulating effect directly on the UPR signaling pathways or on a feedback mechanism on the UPR. Out of the three branches of the UPR, the ATF6 pathway is the most likely to be influenced by Rab6 action. The generation of the active ATF6 transcription factor (ATF6-p50) is preceded by proteolytic processing of fulllength ATF6(-p90) for which transport to the Golgi apparatus is necessary. To investigate whether Rab6 affects ATF6 processing, a CHO cell model was used that stably expresses an N-terminal 3xFLAG tagged ATF6. The production of ATF6-p50 is a rapid event that is maximal after 8 hours of stimulation with tunicamycin, and ATF6-p50 is no longer observed after prolonged stimulation 240 . High concentrations of tunicamycin are usually very toxic for prolonged incubations, however, shorter incubations allow the use of higher tunicamycin concentrations. In addition, this treatment protocol speeds up ATF6 processing and thereby facilitates the study of this initial signaling event of the UPR under Rab6 overexpression (suppl. fig. 3 ).
Rab6 Wt and -T27N (dominant negative mutant of Rab6) were overexpressed and the induction of ATF6-p50 by treatment with tunicamycin for up to six hours was monitored by western blot analysis ( fig. 3A) . Comparison of the levels and kinetics of ATF6-p50 between mock, Rab6 Wt and -T27N transfected cells shows no differences ( fig. 3A) . Consistently, knockdown of Rab6 also has no effect on the induction of ATF6-p50 ( fig. 3B ).
Another branch of the UPR is the PERK pathway. The downstream effector of PERK is eIF2α, which is phosphorylated to relieve the ER of its translational burden. The induction of phosphorylated eIF2α (peIF2α) by tunicamycin is therefore a measure for activity of the PERK pathway. Rab6 overexpression and knockdown was performed in HeLa cells. After treatment with tunicamycin for 6 hours with a broad range of tunicamyin concentrations, peIF2α induction was analyzed on western blot. The results show that a dose-dependent response of eIF2α phosphorylation is observed, but there are no differences between mock and Rab6 transfected cells ( fig. 4A ) nor between scramble and Rab6 siRNA transfected cells ( fig. 4B ).
These results demonstrate that Rab6 has no effect on the processing of ATF6 and no effect on the phosphorylation of eIF2α. This indicates that the effect of Rab6 on Figure 3. Rab6 has no effect on ATF6 processing. CHO-ATF6 cells were transfected with Rab6 Wt, Rab6 T27N (dominant negative) and empty vector (Mock; A), or were transfected with Rab6-and scramble siRNA (B). Cells were stimulated with 10 µg/mL tunicamycin for the indicated times, up to 6 hours. (A,B) The induction of the ATF6 transcription factor (ATF6-p50) is assessed by western blot analysis. The full-length ATF6 (ATF6-p90) shows as two bands, the upper represents C-terminal glycosylated ATF6 and the lower unglycosylated ATF6. The ATF6-p50 also shows as a doublet, the upper band probably represents the partially processed ATF6-p50 and the lower represents fully processed ATF6-p50. Equal amounts of protein were loaded in each lane and actin was used as a loading control.
the UPR does not target the initial signaling of the UPR. This is further supported by the finding that both Rab6 overexpression and knockdown does not affect BiP and CHOP mRNA levels within 6 hours of treatment with tunicamycin ( fig. 5 ). These results strongly suggest that Rab6 has no effect in the early phase of the UPR and is likely to function downstream of initiation.
Rab6 knockdown impairs recovery of the UPR
To test whether Rab6 affects the UPR via a feedback mechanism, a short tunicamycin pulse treatment was provided and recovery of the UPR was analyzed. HeLa cells transfected with scramble or Rab6 siRNA were treated for 1 hour with tunicamycin (1 µg/mL) and allowed to recover from the stressor for 3, 6 and 9 hours. 'Zero' indicated the control sample without tunicamycin treatment. The induction of BiP and CHOP mRNA was analyzed by qPCR. BiP induction is at control level after 3 hour recovery in the scramble siRNA situation ( fig. 6A ). In contrast, the BiP response for Rab6 knock- down cells remains ~1.5 fold increased, compared to scramble siRNA transfected cells, irrespective of recovery time ( fig. 6A ).
In the scramble siRNA transfected cells, CHOP is still 3-fold (3.4±0.3) higher than control after 3 hours recovery. Nine hours of recovery is sufficient for CHOP mRNA to return to normal levels ( fig. 6B ). In the Rab6 knockdown cells, the CHOP mRNA level decreases during recovery, however, it remains 2-to 2.5 fold higher than in the scramble siRNA cells and is still not completely recovered after 9 hours ( fig. 6B ).
These results show that during recovery from an ER stress insult, BiP and CHOP mRNA levels are increased in Rab6 knockdown cells. These results indicate that Rab6 knockdown impairs recovery from ER stress and suggests a functional role for Rab6 in a feedback mechanism on the UPR.
Discussion
In this study we investigated the functional connection between Rab6 and the UPR. We find that increased Rab6 levels decrease the output of the UPR, and conversely that decreased Rab6 levels augment UPR induction, as shown on mRNA and protein level. We have also shown that this effect of Rab6 does not interfere early in the signalling response of the ATF6 (which requires vesicle transport) and PERK pathways. Although we cannot formally exclude that Rab6 affects the Ire1 signalling pathway, our combined data strongly indicate that Rab6 mediates its effect on the UPR after the initiation. This A B Figure 6 . Rab6 knockdown impairs recovery of the UPR. HeLa cells were transfected with Rab6-and scramble siRNA. Cells were stimulated with 1 µg/mL tunicamycin for 1 hour and cells were washed with complete medium without tunicamycin and allowed to recover from ER stress for 3, 6 and 9 hours on complete culture medium without tunicamycin, 0 indicates the sample without tunicamycin treatment. Relative expression of BiP (A) and CHOP mRNA (B) were analyzed by qPCR. EEF1A1 was used as a reference gene. Shown are mean and SD in arbitrary units (AU; n=3, ** and *** indicate a statistical significance level of p≤0.01 and p≤0.001, respectively). Sc: Scramble and R6: Rab6 siRNA.
. Transport out of the ER will reduce the protein load and may be a manner to relieve the stress. Rab1 was shown to function in this way to resolve ER stress in models for Parkinson's disease 244 . Alternatively, Rab6 mediated transport may facilitate an autophagic process. This is an interesting option in view of our recent data that during UPR activation, autophagy is the major degradational pathway
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. Rab1 was recently implicated in the formation of autophagosomes from the ER in response to α-synuclein 245 , indicating the involvement of Rab proteins in regulated autophagy. In addition, an autophagy-like process was shown to be involved in the regulation of ERAD
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. The precise trafficking pathway that is involved in the modulation of the UPR will be the subject of future investigation.
The UPR is an important protective stress mechanism that may become destructive if not adequately regulated. It appears that if ER homeostasis is restored, the apoptotic pathway is the most important process to limit. Our data indicate that the expression of the major UPR regulated pro-apoptotic factor, CHOP, is strongly affected by Rab6. This suggests that the negative effects of prolonged ER stress can be targeted via Rab6. Increasing the function of Rab6 therefore allows modulation of the UPR without directly interfering in the UPR signalling. However, the UPR is activated despite high Rab6 levels in AD neurons. The increased Rab6 expression is predominantly found in non-tangle bearing neurons which have diffuse phosphorylated tau in AD brain, opposed by tangle bearing neurons which lack this increased Rab6 expression 226 . We therefore suggest that Rab6 levels are indeed increased as a protective response, this is supported by the data that show that Rab6 protects against ER stress mediated toxicity. Even though our current data provide evidence from non-neuronal cell based experiments, the UPR is a universal homeostatic response which is found in all cells, including neurons.
Since Rab6 is not induced by the UPR
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, it remains elusive what the trigger is to increase Rab6 levels. It is possible that the pathological state in AD forces these increased levels and that under more physiological UPR conditions Rab6 is regulated at a different level. For example, a rapid regulatory mechanism is provided by the GDP-GTP switch that controls the activity of Rab proteins; active GTP-bound Rab6 is associated with membranes, whereas GDP-bound Rab6 is inactive and localized in the cytosol 180, 186 .
The question still remains why the UPR activation is not resolved by the high Rab6 levels in AD neurons. The answer may be downstream of the trafficking such as the impairment of the autophagy/lysosomal system as observed early in AD pathogenesis 247 . In AD hippocampus, we observe the activated UPR predominantly in neurons that have disturbances in the autophagy/lysosomal system 64, 169 . Recently a role for presenilin in lysosomal function was reported
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, which may provide an interesting connection to our previous work that indicated that the membrane association of Rab6 is dependent on presenilin 1
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. Further studies are required to establish how Rab6 attenuates the UPR and which part of the Rab6 mediated recovery pathway is dysfunctional in AD. This may lead to a novel target for intervention in neurodegenerative diseases that are associated with UPR activation, like Alzheimer's disease. 
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Supplementary figure 3. ATF6 cleavage is elevated at higher tunicamycin concentrations. CHO-ATF6 cells were treated with the indicated concentrations tunicamycin for 6 hours and ATF6 cleavage was assessed on western blot in biological duplicate. Equal amounts of protein were loaded in each lane and actin was used as a loading control.
